To assess the effect of PKM2 nuclear translocation on oxaliplatin resistance in pancreatic cancer, CAFs were pretreated with PKM2 nuclear translocation inhibitor (shikonin) and transfected with circABCC4, and then co-cultured with pancreatic cancer cells. The gene discussed is PKM; the disease is pancreatic neoplasm.